Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

This study is testing whether adding a drug called roginolisib to an existing cancer immunotherapy (tebentafusp) can help improve outcomes for people with metastatic uveal melanoma — a rare eye cancer that has spread. The combination is designed to help the immune system stay active and keep fighting the cancer longer. **You may be eligible if...** - You are 18 or older with metastatic or inoperable uveal melanoma - You carry a specific immune marker called HLA-A*02:01 (a blood test can determine this) - You are currently receiving tebentafusp as your first-line treatment - Any side effects from tebentafusp have resolved to mild or no symptoms - Your overall health and ability to function is rated good (ECOG 0 or 1) - You are willing to use highly effective contraception during and for 6 months after treatment **You may NOT be eligible if...** - You have untreated or symptomatic brain metastases - You have significant heart, liver, or immune-related health conditions - You are pregnant or breastfeeding - You have previously received certain immunosuppressive treatments Talk to your doctor to see if this trial is right for you.